Jones Financial Companies
SUPN icon

Jones Financial Companies’s Supernus Pharmaceuticals SUPN Stock Holding History

Jones Financial Companies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
5,014
-75
-1% -$3.6K ﹤0.01% 2507
2026
Q1 		$252K Buy
5,089
+3,710
+269% +$189K ﹤0.01% 2313
2025
Q4 		$68.5K Buy
1,379
+1,358
+6,467% +$66K ﹤0.01% 2392
2025
Q3 		$988 Hold
21
– – ﹤0.01% 3901
2025
Q2 		$654 Buy
+21
New +$673 ﹤0.01% 3753

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Jones Financial Companies's SUPN Position: Q2 2026 in Review

Jones Financial Companies reduced its Supernus Pharmaceuticals (SUPN) stake by 1.5% in Q2 2026, selling an estimated $3.6K and leaving 5,014 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #2507.

Jones Financial Companies first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. The position peaked at $252K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Jones Financial Companies held 5,014 shares of Supernus Pharmaceuticals worth $235K as of Q2 2026.
  • Jones Financial Companies sold 75 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.6K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #2507 holding.
  • Jones Financial Companies first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's Supernus Pharmaceuticals position peaked at $252K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.